MCID: CRY014
MIFTS: 48

Cryptococcal Meningitis

Categories: Infectious diseases, Neuronal diseases

Aliases & Classifications for Cryptococcal Meningitis

MalaCards integrated aliases for Cryptococcal Meningitis:

Name: Cryptococcal Meningitis 12 15 17
Meningitis, Cryptococcal 43 71
Meningitis Cryptococcal 54

Classifications:



External Ids:

Disease Ontology 12 DOID:0080159
MeSH 43 D016919
UMLS 71 C0085436

Summaries for Cryptococcal Meningitis

Disease Ontology : 12 A fungal meningitis that has material basis in Crypococcus fungal infection.

MalaCards based summary : Cryptococcal Meningitis, also known as meningitis, cryptococcal, is related to meningitis and acquired immunodeficiency syndrome. An important gene associated with Cryptococcal Meningitis is ADA (Adenosine Deaminase), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Amphotericin B and Stavudine have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and t cells, and related phenotypes are hematopoietic system and immune system

Wikipedia : 74 Cryptococcosis, sometimes informally called crypto, is a potentially fatal fungal disease caused by a... more...

Related Diseases for Cryptococcal Meningitis

Diseases related to Cryptococcal Meningitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 404)
# Related Disease Score Top Affiliating Genes
1 meningitis 32.4 VEGFA MBL2 IFNG CSF2 ADA
2 acquired immunodeficiency syndrome 30.7 IFNG CSF2 CD4 CCR6 ADA
3 human immunodeficiency virus type 1 30.7 SRC MAPK10 IFNG CD4 ADA
4 bacterial meningitis 30.5 MBL2 IFNG CSF2
5 choroiditis 30.4 VEGFA IFNG CD4
6 meningoencephalitis 30.4 PLB1 CD4 CCR6
7 cryptococcosis 30.3 PLB1 MBL2 IFNG CSF2 CD4 CCR6
8 sarcoidosis 1 30.2 IFNG CD4 CCR6 ADA
9 central nervous system tuberculosis 30.2 IFNG CD4 ADA
10 miliary tuberculosis 30.2 IFNG CD4 ADA
11 sporotrichosis 30.2 MBL2 IFNG CD4
12 hypersplenism 30.1 IFNG CSF2 CD4
13 cryptosporidiosis 30.1 MBL2 IFNG CD4
14 pericarditis 30.1 IFNG CD4 ADA
15 bacillary angiomatosis 30.0 VEGFA CD4
16 candidiasis 30.0 PLB1 MBL2 IFNG CSF2 CCR6
17 extrapulmonary tuberculosis 30.0 MBL2 IFNG CD4 ADA
18 relapsing-remitting multiple sclerosis 29.9 TNFSF13B IFNG CSF2 CCR6
19 histoplasmosis 29.9 IFNG CD4 CCR6
20 pulmonary sarcoidosis 29.9 IFNG CSF2 CCR6
21 bacterial infectious disease 29.9 MBL2 IFNG CSF2 CD4 CCR6
22 central nervous system lymphoma 29.9 TNFSF13B TNFRSF13C CCR6
23 lymphadenitis 29.8 IFNG CD4 CCR6
24 macroglobulinemia 29.7 TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B
25 anemia, autoimmune hemolytic 29.7 TNFSF13B TNFRSF13B CD4 CCR6
26 hyper ige syndrome 29.7 IFNG CSF2 CCR6
27 chronic mucocutaneous candidiasis 29.7 IFNG CSF2 CD4 CCR6
28 central nervous system vasculitis 29.7 IFNG CD4 CCR6
29 nervous system disease 29.7 VEGFA IFNG CSF2 CD4 CCR6
30 coccidioidomycosis 29.7 MBL2 CD4 CCR6
31 immune deficiency disease 29.6 TNFSF13B TNFRSF13B MBL2 IFNG CSF2 CD4
32 fungal infectious disease 29.6 PLB1 IFNG CSF2 CD4 CCR6
33 cellulitis 29.6 IFNG CD4 CCR6
34 chickenpox 29.5 IFNG CD4 CCR6 ADA
35 bacterial pneumonia 29.5 CD4 CCR6 ADA
36 exanthem 29.5 VEGFA IFNG CSF2 CD4 CCR6
37 nocardiosis 29.5 IFNG CD4
38 opportunistic mycosis 29.3 PLB1 IFNG CSF2 CD4 CCR6
39 cytomegalovirus retinitis 29.3 IFNG CSF2 CD4 CARTPT
40 progressive multifocal leukoencephalopathy 29.3 CD4 CCR6 CARTPT
41 thrombocytopenia 29.2 TNFSF13B TNFRSF13C TNFRSF13B SRC MBL2 IFNG
42 pulmonary disease, chronic obstructive 29.1 SRC CSF2 CD4 CCR6
43 pneumocystosis 29.0 CD4 CCR6 CARTPT
44 connective tissue disease 28.9 VEGFA TNFSF13B TNFSF13 IFNG CD4 CCR6
45 multiple sclerosis 28.9 TNFSF13B TNFRSF13C MBL2 IFNG CSF2 CD4
46 fungal meningitis 28.9 PLB1 IFNG CSF2 CD4 CCR6 CARTPT
47 syphilis 28.8 IFNG CD4 CCR6 CARTPT
48 malaria 28.7 VEGFA TNFSF13B MBL2 IFNG FCGR2B CSF2
49 leukemia, acute lymphoblastic 28.6 CSF2 CD4 CCR6 CARTPT ADA
50 human immunodeficiency virus infectious disease 28.2 MBL2 IFNG CSF2 CD4 CCR6 CARTPT

Comorbidity relations with Cryptococcal Meningitis via Phenotypic Disease Network (PDN):


Acute Cystitis Cryptococcosis
Deficiency Anemia

Graphical network of the top 20 diseases related to Cryptococcal Meningitis:



Diseases related to Cryptococcal Meningitis

Symptoms & Phenotypes for Cryptococcal Meningitis

MGI Mouse Phenotypes related to Cryptococcal Meningitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.32 ADA ARRB2 CARTPT CCR6 CD4 CSF2
2 immune system MP:0005387 10.19 ADA ARRB2 CARTPT CCR6 CD4 CSF2
3 homeostasis/metabolism MP:0005376 10.13 ADA ARRB2 CARTPT CCR6 CD4 CSF2
4 endocrine/exocrine gland MP:0005379 10.06 ADA CARTPT CD4 CSF2 FCGR2B IFNG
5 normal MP:0002873 9.81 ADA CCR6 CD4 FCGR2B IFNG TNFRSF17
6 renal/urinary system MP:0005367 9.56 ADA CSF2 EFS FCGR2B IFNG MBL2
7 respiratory system MP:0005388 9.23 ADA ARRB2 CSF2 EFS FCGR2B IFNG

Drugs & Therapeutics for Cryptococcal Meningitis

Drugs for Cryptococcal Meningitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 78)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amphotericin B Approved, Investigational Phase 4 1397-89-3 5280965 14956
2
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
3
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
4
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
5
Zidovudine Approved Phase 4 30516-87-1 35370
6
Nevirapine Approved Phase 4 129618-40-2 4463
7
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
8
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
9 Liposomal amphotericin B Phase 4
10 Anti-HIV Agents Phase 4
11 Reverse Transcriptase Inhibitors Phase 4
12 Anti-Retroviral Agents Phase 4
13 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4
14 Liver Extracts Phase 4
15
Meloxicam Approved, Vet_approved Phase 3 71125-38-7 54677470 5281106
16
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
17
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
18
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
19
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
20
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
21
Sertraline Approved Phase 3 79617-96-2 68617
22 Analgesics, Non-Narcotic Phase 3
23 Cyclooxygenase 2 Inhibitors Phase 3
24 Analgesics Phase 3
25 Cyclooxygenase Inhibitors Phase 3
26 Anti-Inflammatory Agents, Non-Steroidal Phase 3
27 Antirheumatic Agents Phase 3
28 Cytochrome P-450 CYP3A Inhibitors Phase 3
29 Anti-Infective Agents, Local Phase 3
30 Gastrointestinal Agents Phase 3
31 Antineoplastic Agents, Hormonal Phase 3
32 Antiemetics Phase 3
33 glucocorticoids Phase 3
34 Anti-Inflammatory Agents Phase 3
35 Antitubercular Agents Phase 3
36 Amebicides Phase 3
37 Antiprotozoal Agents Phase 3
38 Anti-Bacterial Agents Phase 3
39 Antiparasitic Agents Phase 3
40 Cytochrome P-450 Enzyme Inhibitors Phase 3
41 Hormone Antagonists Phase 3
42 Hormones Phase 3
43 Anti-Infective Agents Phase 3
44 Antifungal Agents Phase 3
45 Antidepressive Agents Phase 3
46 Psychotropic Drugs Phase 3
47 Serotonin Uptake Inhibitors Phase 3
48 Neurotransmitter Agents Phase 3
49
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
50
deoxycholic acid Approved Phase 1, Phase 2 83-44-3 222528

Interventional clinical trials:

(show top 50) (show all 59)
# Name Status NCT ID Phase Drugs
1 Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis Without Acquired Immune Deficiency Syndrome Unknown status NCT02686853 Phase 4 Liposomal amphotericin B
2 Trial for the Optimal Timing of HIV Therapy After Cryptococcal Meningitis Completed NCT01075152 Phase 4 efavirenz
3 Operational Research for Cryptococcal Antigen Screening to Improve ART Survival Completed NCT01535469 Phase 4 Fluconazole
4 A Randomized Clinical Trial of Immediate Versus Standard Antiretroviral Therapy for HIV-infected Adults Presenting With Cryptococcal Meningitis Completed NCT00976040 Phase 4
5 Safety, Efficacy, and Pharmacokinetics of Amphotericin B Lipid Complex at 10 mg/kg/d for 7 Days or 5.0 mg/kg/d for 14 Days as Induction Therapy for Disseminated Cryptococcosis in Patients With HIV Completed NCT01656382 Phase 4 ABLC
6 Evaluation of World Health Organization (WHO) Recommendations on Test and Treat Strategy, Managing Advanced HIV Disease and Rapid Initiation of ART Among People Living With HIV in Nepal: A Cluster Randomized Trial. Active, not recruiting NCT03723525 Phase 4
7 Prospective Pilot Study to Evaluate a Standardized Management of Cryptococcal Meningitis in Patients Infected With HIV in Sub-Saharan Africa Involving an Initial Combination Therapy With Fluconazole and Flucytosine in High Doses, Complemented by Repeat Lumbar Punctures Unknown status NCT01715922 Phase 2, Phase 3 Fluconazole;Flucytosine
8 A Double-Blind Randomized Placebo Controlled Trial for Prevention of Tuberculosis-Immune Reconstitution Inflammatory Syndrome With Non-Steroid Anti-Inflammatory Drugs (NSAIDs) in HIV-Infected Adults Unknown status NCT02060006 Phase 3 Meloxicam 7.5mg daily for 8 weeks
9 Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis Completed NCT01802385 Phase 3 Sertraline
10 Comparison of Fluconazole (UK-49,858) and Amphotericin B for Maintenance Treatment of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome Completed NCT00001017 Phase 3 Fluconazole;Amphotericin B
11 Rapid Diagnostic Tests in Association With Clinical and Laboratory Predictors for the Diagnosis of Neglected Tropical Diseases in Patients With Neurological Disorders in Rural Hospitals of Bandundu,Democratic Republic of Congo Completed NCT01589289 Phase 3
12 Randomized Comparative Study of Fluconazole Versus Clotrimazole Troches in the Prevention of Serious Fungal Infection in Patients With AIDS or Advanced AIDS-Related Complex. (A Nested Study of ACTG 081) Completed NCT00000676 Phase 3 Clotrimazole;Fluconazole
13 Evaluation of CrAg Screening With Enhanced Antifungal Therapy for Asymptomatic CrAg+ Persons Recruiting NCT03945448 Phase 2, Phase 3 Single dose liposomal Amphotericin and Fluconazole;Fluconazole
14 A Randomized Double Blind Placebo Controlled Trial of Adjunctive Dexamethasone for the Treatment of HIV-infected Adults With Tuberculous Meningitis Recruiting NCT03092817 Phase 3 Dexamethasone
15 Antifungal Treatment of Cryptococcal Meningitis Not yet recruiting NCT04140461 Phase 3 Amphotericin B;Flucytosine
16 Cryptococcal Antigen Screening Plus Sertraline Terminated NCT03002012 Phase 3 Sertraline;Placebo Oral Tablet;Fluconazole
17 Dexamethasone in Cryptococcal Meningitis Completed NCT00000776 Phase 2 Flucytosine;Fluconazole;Amphotericin B;Dexamethasone
18 A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase II Study of the Safety and Antifungal Activity of Subcutaneous Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) in Conjunction With Standard Therapy in Patients With Acute Cryptococcal Meningitis Completed NCT00012467 Phase 2 Itraconazole;Flucytosine;Fluconazole;Amphotericin B;Interferon gamma-1b
19 A Randomized Trial of Tamoxifen Combined With Amphotericin B and Fluconazole for Cryptococcal Meningitis Completed NCT03112031 Phase 2 Tamoxifen;Amphotericin B;Fluconazole
20 A Phase II Randomized Trial of Amphotericin B Alone or Combined With Fluconazole in the Treatment of AIDS-Associated Cryptococcal Meningitis Completed NCT00145249 Phase 2 Amphotericin B;Fluconazole
21 A Phase I/II Dose-Finding Study of High-Dose Fluconazole Treatment in AIDS-Associated Cryptococcal Meningitis Completed NCT00885703 Phase 1, Phase 2 Fluconazole;Amphotericin B
22 Pilot Study To Determine the Feasibility of Itraconazole for Primary Treatment and Suppression of Relapse of Disseminated Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome Completed NCT00000975 Phase 2 Itraconazole
23 Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial Recruiting NCT04031833 Phase 1, Phase 2 MAT2203;Amphotericin B
24 Valganciclovir for Suppression of HHV-8 Four Weeks Prior to Initiation of cART in Patients With Disseminated Kaposi Sarcoma Compare With Standard Therapy, Its Impact on the Development of IRIS and Attributable Mortality Active, not recruiting NCT03296553 Phase 2 Valganciclovir;Antiretroviral Combinations
25 A Multicenter, Randomized Study to Assess the Efficacy and Safety of Mycograb® as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS Terminated NCT00847678 Phase 2
26 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Mycograb® as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS Terminated NCT00324025 Phase 2 Mycograb;placebo
27 An Open Label Randomized Controlled Phase IIb Trial to Determine the Safety of Oral Fluconazole in Combination With Flucytosine as Compared to Fluconazole Alone Terminated NCT01562132 Phase 2 Flucytosine and fluconazole;Fluconazole
28 Sertraline in Addition to Standard of Care Treatment for Coccidioidomycosis Withdrawn NCT02908334 Phase 2 Sertraline
29 Vietnam Cryptococcal Retention in Care Study (CRICS) Federal Financial Report From June 2015 to June 2016 Completed NCT02955862 Phase 1
30 Phase I Study to Evaluate the Safety and Tolerance of RMP-7 Administered With Amphotericin B to Patients With HIV Infection and Cryptococcal Meningitis Completed NCT00002316 Phase 1 Lobradimil;Amphotericin B
31 SCH 39304 as Therapy for Acute Cryptococcal Meningitis in HIV-Infected Patients Followed by Maintenance Therapy Completed NCT00000677 Phase 1 SCH 39304
32 A Randomized Study to Evaluate the Safety and Efficacy of Liposomal Amphotericin B and Amphotericin B Deoxycholate With or Without Flucytosine Followed by Fluconazole, for the Treatment of Cryptococcal Meningitis Unknown status NCT02136030 Liposomal amphotericin B;Amphotericin B-deoxycholate
33 Evaluation of a Public Health Strategy to Improve Survival of HIV Infected Patients Unknown status NCT02334670 Fluconazole
34 Implementation and Evaluation of a Screening Strategy to Reduce Morbidity and Mortality Due to Cryptoccocal Meningo-encephalitis in ART Naive AIDS Patients With <100 CD4 Count at the Day Hospital of the Yaounde Central Hospital, Cameroon Unknown status NCT02624453 Fluconazole;Antiretroviral therapy
35 Vietnam Cryptococcal Retention in Care Study (CRICS) - Version 2.1 Unknown status NCT03267407
36 A Cross-Sectional Study of HIV-Related Neurological Disorders in Ten Countries of the Asia Pacific Region Unknown status NCT00168246
37 Pilot Study of Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis Completed NCT00002076 Fluconazole
38 Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis Completed NCT00002305 Flucytosine;Fluconazole;Amphotericin B
39 Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis Completed NCT00002075 Flucytosine;Fluconazole;Amphotericin B
40 A Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis Completed NCT00002068 Fluconazole;Amphotericin B
41 Double Blind Placebo Controlled Study of Fluconazole (UK-49,858) for Maintenance Treatment of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome Completed NCT00002294 Fluconazole
42 Multi-Center Evaluation of Fluconazole (UK-49,858) as Treatment for Acute Cryptococcal Meningitis in Patients Who Have Failed to Respond or Have Experienced Unacceptable Toxicity During Treatment With Amphotericin B Completed NCT00002306 Fluconazole
43 An Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis Completed NCT00002077 Fluconazole
44 Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis Completed NCT00002040 Fluconazole
45 Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Maintenance Treatment for the Prevention of Relapse of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome Completed NCT00002074 Fluconazole;Amphotericin B
46 Safety and Efficacy of Amphotericin B Lipid Complex in the Treatment of Cryptococcal Meningitis in Patients With the Acquired Immunodeficiency Syndrome Completed NCT00002019 Amphotericin B, Lipid-based;Amphotericin B
47 A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis Completed NCT00000639 Itraconazole;Flucytosine;Fluconazole;Amphotericin B
48 A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis. Completed NCT00002113 Flucytosine;Fluconazole
49 Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis Completed NCT00000708 Flucytosine;Fluconazole;Amphotericin B
50 Randomized Control Trial of Early vs Delayed ART in the Treatment of Cryptococcal Meningitis. Completed NCT00830856 Fluconazole;Fixed dose - Stavudine, lamivudine and Nevirapine;Fixed dose - Stavudine, Lamivudine, Nevirapine

Search NIH Clinical Center for Cryptococcal Meningitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Fluconazole
Flucytosine

Cochrane evidence based reviews: meningitis, cryptococcal

Genetic Tests for Cryptococcal Meningitis

Anatomical Context for Cryptococcal Meningitis

MalaCards organs/tissues related to Cryptococcal Meningitis:

40
Testes, Brain, T Cells, Liver, Bone, Kidney, Monocytes

Publications for Cryptococcal Meningitis

Articles related to Cryptococcal Meningitis:

(show top 50) (show all 2435)
# Title Authors PMID Year
1
Cerebrospinal fluid adenosine deaminase activity for the diagnosis of tuberculous meningitis in adults. 54 61
17333738 2006
2
Cerebrospinal fluid adenosine deaminase levels in a patient with cryptococcal meningitis. 61 54
1457651 1992
3
[Cryptococcal meningitis in patients with AIDS: combined treatment with amphotericin B and fluconazole, and high levels of adenosine deaminase in cerebrospinal fluid]. 61 54
1620927 1992
4
"False negative" CSF cryptococcal antigen with clinical meningitis: Case reports and review of literature. 61
32566468 2020
5
Cryptococcal meningitis in a patient with multiple sclerosis on dimethyl fumarate treatment: A case report. 61
32408151 2020
6
A correlation analysis between clinical manifestations, therapeutic strategies, and the prognosis of children with cryptococcal meningitis in China. 61
32243916 2020
7
CNS infections in HIV. 61
32332225 2020
8
Anti-Cryptococcal activity of a furanone derivative-antibiofilm and opsonophagocytic potential. 61
32037102 2020
9
Cryptococcus Meningitis Can Co-occur with Anti-NMDA Receptor Encephalitis. 61
32522922 2020
10
Time to embrace access programmes for medicines: lessons from the South African flucytosine access programme. 61
32126322 2020
11
Clinical and Radiographic Features of Cryptococcal Neoformans Meningitis-associated Immune Reconstitution Inflammatory Syndrome. 61
32561831 2020
12
HIV-1 Central Nervous System Compartmentalization and Cytokine Interplay in Non-Subtype B HIV-1 Infections in Nigeria and Malawi. 61
31914800 2020
13
IL-25 Receptor Signaling Modulates Host Defense against Cryptococcus neoformans Infection. 61
32561567 2020
14
Cryptococcal antigenemia and its predictors among HIV infected patients in resource limited settings: a systematic review. 61
32527231 2020
15
The prevalence of cryptococcal antigen (CrAg) and benefits of pre-emptive antifungal treatment among HIV-infected persons with CD4+ T-cell counts < 200 cells/μL: evidence based on a meta-analysis. 61
32532212 2020
16
The Novel J-Domain Protein Mrj1 Is Required for Mitochondrial Respiration and Virulence in Cryptococcus neoformans. 61
32518190 2020
17
Current burden of serious fungal infections in Republic of Congo. 61
32181941 2020
18
[Probable rheumatoid meningitis complicated by cryptococcal meningitis: A case report]. 61
32435045 2020
19
Comparison of cryptococcal meningitis in HIV-negative patients with and without lung infections. 61
32527201 2020
20
Necrotizing fungal osteomyelitis and fingolimod, 4 years after treatment with fingolimod. 61
32126512 2020
21
Steroid in cryptococcal meningitis. 61
32291241 2020
22
Cryptococcal meningitis in an immunocompetent patient. 61
32534877 2020
23
Cryptococcal meningitis: a review of cryptococcal antigen screening programs in Africa. 61
32567406 2020
24
HIV infection does not increase 10-week mortality of Chinese cryptococcal meningitis patients. 61
32539429 2020
25
Postinfectious inflammatory response syndrome in HIV-uninfected and nontransplant men after cryptococcal meningitis. 61
32490698 2020
26
Landmark clinical observations and immunopathogenesis pathways linked to HIV and Cryptococcus fatal central nervous system co-infection. 61
32472727 2020
27
Cryptococcus meningitis mimicking cerebral septic emboli, a case report series demonstrating injection drug use as a risk factor for development of disseminated disease. 61
32460792 2020
28
Evaluation of Clinical Profile, Diagnostic Tests, And Prognosis of Cryptococcal Meningitis in HIV Infected Patients in Western India. 61
32416706 2020
29
Late Presenters of HIV Infection in an HIV Unit of a Tertiary University Hospital in a Rural Region of Greece. 61
32295383 2020
30
Reduction of Human DNA Contamination in Clinical Cerebrospinal Fluid Specimens Improves the Sensitivity of Metagenomic Next-Generation Sequencing. 61
32002752 2020
31
Framework for the implementation of advanced HIV disease diagnostics in sub-Saharan Africa: programmatic perspectives. 61
32473102 2020
32
[Cryptococcal meningitis in the treatment of CLL with ibrutinib: a case report and literature review]. 61
32536143 2020
33
Cryptococcal Meningitis Screening and Community-based Early Adherence Support in People With Advanced Human Immunodeficiency Virus Infection Starting Antiretroviral Therapy in Tanzania and Zambia: A Cost-effectiveness Analysis. 61
31149704 2020
34
Cryptococcal-related Mortality Despite Fluconazole Preemptive Treatment in a Cryptococcal Antigen Screen-and-Treat Program. 61
31179488 2020
35
MiR-30c-5p mediates inflammatory responses and promotes microglia survival by targeting eIF2α during Cryptococcus neoformans infection. 61
31958475 2020
36
Cryptococcosis in pregnancy and the postpartum period: Case series and systematic review with recommendations for management. 61
31689712 2020
37
New Approaches for Cryptococcosis Treatment. 61
32340403 2020
38
Multicenter Cryptococcal Antigen Screening of HIV-Infected Patients in Iran. 61
32296917 2020
39
A Rare Case of Isolated Pulmonary Cryptococcoma in an Immunocompromised Host. 61
32455065 2020
40
Infective patterns of cryptococcosis in patients with connective tissue disease: a retrospective study. 61
32246239 2020
41
Cytokine profiles in cerebrospinal fluid of patients with meningitis at a tertiary general hospital in China. 61
30448438 2020
42
Standardized Urine-Based Tuberculosis (TB) Screening With TB-Lipoarabinomannan and Xpert MTB/RIF Ultra in Ugandan Adults With Advanced Human Immunodeficiency Virus Disease and Suspected Meningitis. 61
32373646 2020
43
Pharmacokinetics of flucytosine in a critically ill patient on continuous venovenous hemodiafiltration. 61
32236456 2020
44
A Case of Severe Cryptococcal Immune Reconstitution Inflammatory Syndrome Presenting with Brain and Intradural Abscesses in an HIV Patient. 61
32342852 2020
45
Ventriculoperitoneal shunt insertion in human immunodeficiency virus infected adults: a systematic review and meta-analysis. 61
32303190 2020
46
Neurological worsening during treatment of an immunocompetent adult with Cryptococcus neoformans meningitis. 61
31993318 2020
47
Cryptococcus gattii infection in an immunocompetent host in Greece. 61
31867171 2020
48
Human IgM Inhibits the Formation of Titan-Like Cells in Cryptococcus neoformans. 61
31988178 2020
49
Efficacy of Cerebrospinal Fluid Beta-d-Glucan Diagnostic Testing for Fungal Meningitis: a Systematic Review. 61
31996446 2020
50
The cost-effectiveness of prophylaxis strategies for individuals with advanced HIV starting treatment in Africa. 61
32219991 2020

Variations for Cryptococcal Meningitis

Expression for Cryptococcal Meningitis

Search GEO for disease gene expression data for Cryptococcal Meningitis.

Pathways for Cryptococcal Meningitis

Pathways related to Cryptococcal Meningitis according to GeneCards Suite gene sharing:

(show all 28)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.84 VEGFA TNFSF13B TNFSF13 TNFRSF17 TNFRSF13C TNFRSF13B
2
Show member pathways
13.74 VEGFA TNFSF13B TNFSF13 TNFRSF17 TNFRSF13C TNFRSF13B
3
Show member pathways
13.58 TNFSF13B TNFSF13 TNFRSF17 TNFRSF13C TNFRSF13B SRC
4
Show member pathways
13.46 VEGFA TNFSF13B TNFRSF17 TNFRSF13C SRC MAPK10
5
Show member pathways
13.17 TNFSF13B TNFSF13 TNFRSF17 TNFRSF13C TNFRSF13B SRC
6
Show member pathways
13.04 YWHAG TNFSF13B TNFSF13 TNFRSF17 TNFRSF13C TNFRSF13B
7
Show member pathways
12.99 YWHAG VEGFA TNFSF13B TNFSF13 SRC MAPK10
8
Show member pathways
12.81 VEGFA TNFSF13B TNFSF13 TNFRSF17 TNFRSF13C TNFRSF13B
9
Show member pathways
12.67 VEGFA TNFSF13B TNFSF13 TNFRSF17 TNFRSF13C TNFRSF13B
10
Show member pathways
12.51 VEGFA SRC MAPK10 FCGR2B CSF2
11 12.25 TNFRSF13C MAPK10 CSF2 CD4
12
Show member pathways
12.2 TNFSF13B TNFSF13 TNFRSF17 TNFRSF13C TNFRSF13B SRC
13 12.15 SRC MAPK10 IFNG FCGR2B
14 12.01 VEGFA SRC MAPK10 IFNG
15 11.82 VEGFA TNFSF13B TNFSF13 IFNG CSF2
16
Show member pathways
11.76 YWHAG TNFSF13B TNFSF13 TNFRSF17 TNFRSF13C TNFRSF13B
17 11.74 YWHAG SRC MAPK10 ARRB2
18
Show member pathways
11.74 TNFSF13B TNFSF13 TNFRSF17 TNFRSF13C TNFRSF13B
19 11.72 MAPK10 IFNG CSF2
20 11.71 IFNG CD4 CCR6
21 11.67 SRC CD4 ARRB2
22
Show member pathways
11.67 TNFSF13B TNFSF13 TNFRSF17 TNFRSF13B
23 11.66 IFNG CSF2 CD4
24
Show member pathways
11.57 VEGFA IFNG CSF2
25 11.36 TNFRSF13C TNFRSF13B CD4 ADA
26 11.25 TNFRSF13B SRC CSF2
27 11.19 IFNG CSF2 CD4
28 10.78 SRC ARRB2

GO Terms for Cryptococcal Meningitis

Cellular components related to Cryptococcal Meningitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.76 VEGFA TNFSF13B TNFSF13 MBL2 IFNG CSF2
2 plasma membrane GO:0005886 9.47 TNFSF13B TNFSF13 TNFRSF17 TNFRSF13C TNFRSF13B SRC
3 external side of plasma membrane GO:0009897 9.35 TNFRSF13C FCGR2B CD4 CCR6 ADA

Biological processes related to Cryptococcal Meningitis according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.11 VEGFA TNFSF13B TNFSF13 TNFRSF17 SRC MAPK10
2 positive regulation of gene expression GO:0010628 10.01 VEGFA SRC IFNG CSF2 ARRB2
3 adaptive immune response GO:0002250 9.98 TNFRSF17 TNFRSF13C TNFRSF13B IFNG CD4
4 immune response GO:0006955 9.87 TNFSF13B TNFSF13 IFNG FCGR2B CSF2 CD4
5 positive regulation of protein phosphorylation GO:0001934 9.86 VEGFA IFNG CD4 ARRB2
6 immune system process GO:0002376 9.86 TNFSF13B TNFSF13 TNFRSF17 TNFRSF13C TNFRSF13B SRC
7 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.78 VEGFA SRC ARRB2
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.77 VEGFA IFNG CSF2
9 positive regulation of T cell proliferation GO:0042102 9.75 TNFSF13B TNFRSF13C CD4
10 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.73 VEGFA SRC CD4 ARRB2
11 T cell costimulation GO:0031295 9.72 TNFSF13B TNFRSF13C SRC
12 positive regulation of phagocytosis GO:0050766 9.7 MBL2 IFNG FCGR2B
13 positive regulation of B cell proliferation GO:0030890 9.65 TNFSF13B TNFRSF13C ADA
14 positive regulation of epithelial cell migration GO:0010634 9.63 SRC IFNG CCR6
15 positive regulation of podosome assembly GO:0071803 9.62 SRC CSF2
16 cellular response to granulocyte macrophage colony-stimulating factor stimulus GO:0097011 9.59 CSF2 CD4
17 B cell homeostasis GO:0001782 9.58 TNFSF13B TNFRSF13C TNFRSF13B
18 regulation of circadian sleep/wake cycle, sleep GO:0045187 9.57 CSF2 ADA
19 tumor necrosis factor-mediated signaling pathway GO:0033209 9.55 TNFSF13B TNFSF13 TNFRSF17 TNFRSF13C TNFRSF13B
20 positive regulation of interleukin-23 production GO:0032747 9.54 IFNG CSF2
21 B cell costimulation GO:0031296 9.51 TNFSF13B TNFRSF13C
22 histamine secretion GO:0001821 9.49 CSF2 ADA
23 macrophage differentiation GO:0030225 9.26 VEGFA IFNG CSF2 CD4
24 positive regulation of germinal center formation GO:0002636 8.8 TNFSF13B TNFRSF13C ADA

Molecular functions related to Cryptococcal Meningitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein domain specific binding GO:0019904 9.56 YWHAG SRC EFS ARRB2
2 signaling receptor activity GO:0038023 9.46 TNFRSF17 TNFRSF13B CD4 CCR6
3 cytokine activity GO:0005125 9.35 VEGFA TNFSF13B TNFSF13 IFNG CSF2
4 signaling receptor binding GO:0005102 9.1 TNFSF13B TNFSF13 SRC MBL2 CD4 ARRB2

Sources for Cryptococcal Meningitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....